Inhibitor of growth 4 is a member of the inhibitor of growth family proteins, which is involved in cell apoptosis, migration, invasion, and cell cycle progress. In this study, we investigated the inhibitor of growth 4 level in non-small cell lung cancer tissues and explored the antitumor activity of inhibitor of growth 4 in vitro and in vivo using non-small cell lung cancer cell line SPC-A1 and its underlying molecular mechanisms. We also explored its role on the radiosensitivity in SPC-A1 cells. The level of inhibitor of growth 4 protein was significantly decreased in 28 cases of non-small cell lung cancer tissues in comparison with corresponding noncancerous lung epithelial tissues. Upregulation of inhibitor of growth 4 by plasmid pcDNA3.1-ING4 delivery could suppress proliferation and increase apoptosis of SPC-A1 cells both in vitro and in vivo. Additionally, we found that overexpression of inhibitor of growth 4 in SPC-A1 cell line could lead to a higher Bcl-2/Bax ratio, which might be an important factor in the apoptosis regulation. Furthermore, overexpression of inhibitor of growth 4 enhanced the radiosensitivity of SPC-A1 cells to irradiation. Inhibitor of growth 4 upregulation plus radiotherapy induced synergistic tumor suppression in SPC-A1 xenografts implanted in athymic nude mice. Thus, the restoration of inhibitor of growth 4 function might provide a potential strategy for non-small cell lung cancer radiosensitization.
Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 80% of all cases.
1,2 Despite early diagnosis and advances in clinical treatment, patients with NSCLC are often diagnosed at an advanced stage and have a poor prognosis. The 5-year survival rate of NSCLC is only 13%, and the median survival is 8 to 11 months. 3 At present, radiotherapy plays an important role in achieving local control of the NSCLC tumor and in the relief of symptoms resulting from metastatic diseases. 4 However, as a curative modality, radiotherapy has been disappointing. Two major issues that limit the effectiveness of radiotherapy of NSCLC are radioresistance of the tumor and radiation-induced toxicity to normal tissues such as the lung and esophagus. 4 Therefore, it is urgent to exploit novel strategies to overcome the radioresistance of human NSCLC. The inhibitor of growth (ING) gene family is comprised of 5 evolutionarily conserved proteins (ING1-ING5), which have been considered as candidate tumor suppressor genes. [5] [6] [7] [8] They are involved in nucleoprotein modification through their roles in histone acetylation. 9 Recent studies have shown that the ING protein enhances p53 activity and regulates various biological activities, including DNA repair, oncogenesis, cell apoptosis, and cell cycle process. [6] [7] [8] Inhibitor of growth 4 is characterized by a highly conserved C-terminal plant homeodomain finger motif and a potential bipartite nuclear localization signal (NLS) domain. 6 Inhibitor of growth 4 has emerged as a tumor suppressor gene, because its expression was markedly downregulated in multiple human malignancies [10] [11] [12] [13] [14] [15] and the ING4 gene is frequently mutated in various cancer cell lines. 16, 17 Additionally, ING4 expression is associated with pathological features and poor prognosis, suggesting that it might serve as a diagnostic and prognostic marker for human malignancies. 10, 15, 18, 19 Shiseki et al demonstrated that ING4 overexpression could induce a decrease cell population in S phase and apoptosis enhancement in a p53-dependent manner. 6 Inhibitor of growth 4 could induce G 2 /M arrest and enhance chemosensitivity to antitumor agents in human hepatocellular cancer cells. 20, 21 In addition, ING4 was reported to suppress nuclear factor kB (NF-kB) signaling and mediate the transcriptional repression of multiple NF-kB-responsive genes, such as cyclooxygenase (Cox-2), hypoxia-inducible factor 1a, matrix metalloproteinase 2 (MMP-2), MMP-9, CD34 (human hematopoietic stem cell membrane glycoprotein), interleukin 6 (IL-6), and IL-8, leading to angiogenesis inhibition in multiple malignancies. 10, 19, [22] [23] [24] [25] [26] [27] Therefore, these findings revealed that ING4 exerts its tumorsuppressive effects through multiple pathways.
Conventional chemotherapy or radiotherapy together with gene therapy referred as combined therapy is a common practice in human cancer treatment, since it could reduce side effects, reverse chemoresistance to cytotoxic drugs, and improve therapeutic outcome. Recently, several studies have reported that ING4 was significantly decreased in human NSCLC tissues compared with corresponding noncancerous lung tissues. 12, 15 Moreover, downregulation of nuclear ING4 was associated with the tumor stage and lymph node metastasis in NSCLC. 15 Upregulation of ING4 induces cell growth inhibition and triggers apoptosis in the NSCLC cells via multiple pathways. 12, [28] [29] [30] Additionally, adenovirus-mediated upregulation of ING4 gene inhibits microvessel formation through downregulating the expression of CD34 in tumor vessels. We also previously reported that restoration of ING4 expression could reverse chemoresistance of docetaxel-resistant NSCLC cells to docetaxel in vitro and in vivo. 31 To the best of our knowledge, the protective effect of ING4 in combination with radiation therapy on human NSCLCs has not been investigated.
In our previous study, we first detected the expression of ING4 protein in NSCLC tissues by Western blot and immunohistochemistry assays and found that ING4 was markedly downregulated in NSCLC tissues compared with corresponding noncancerous tissues. Then, we constructed a recombinant plasmid pcDNA3.1-ING4 and selected stable transfectant cells to assess the combined effects of ING4 gene plus X-ray against NSCLC cells. We found that overexpression of ING4 could suppress proliferation, increase apoptosis of SPC-A1 cells, and lead to a higher Bcl-2/Bax ratio both in vitro and in vivo. Inhibitor of growth 4 upregulation plus radiotherapy induced synergistic tumor suppression in SPC-A1 cells. Taken together, ING4 could serve as a potential therapeutic target in radiation therapy of NSCLC.
Methods

Ethics Statement
Ethics approval was given by the ethics committee of Nanjing University. Written informed consent was obtained from patients before sampling. The animal experiments were carried out in accordance with the Nanjing University Guide for the Care and Use of Laboratory Animals formulated by the National Society for Medical Research.
Patient and Tissue Samples
Non-small cell lung cancer and adjacent noncancerous tissue samples were obtained at the time of surgery from 28 patients with NSCLC at the Jinling Hospital (China) from 2008 to 2009. Tumor and adjacent noncancerous tissue samples were rapidly frozen in liquid nitrogen after resection and stored at À80 C.
Cell Culture
Human NSCLC cell line SPC-A1 was obtained from the Department of Medical Oncology, Jinling Hospital. SPC-A1 was cultured in Dulbecco-modified Eagle medium (GIBCO, USA) supplemented with 10% fetal bovine serum at 37 C in humidified atmosphere with 5% CO 2 .
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were cut into 3-mmthick sections. The sections were incubated with primary goat monoclonal ING4 antibody (Santa Cruz Biotechnology, Santa Cruz, California), followed by incubation with a secondary antibody (horseradish peroxidase conjugated to goat antigoat immunoglobulin). The adjacent noncancerous lung tissues were selected as a positive control. Negative control consisted of substituting phosphate-buffered saline (PBS) solution for the primary antibody.
The immunostain result of ING4 was evaluated by a semiquantitative scoring system. The percentage of positive cells (score: 1 for <10%; 2 for 11%-50%; 3 for 51%-75%; 4 for >75%) and strength of staining (score: no staining as 0; shallow brown as 1; brown as 2; deep brown as 3) were used to assess the immunoreactivity. The immunohistochemistry score was recorded from the 2 areas: 0 to 2 scores as (À), 3 to 5 as (þ), 6 to 9 as (þþ), and >9 as (þþþ).
Conventional Reverse Transcription Polymerase Chain Reaction Analysis
Total cellular RNA was extracted from cells and was reverse transcribed using reverse transcription polymerase chain reaction (RT-PCR) kits (Applied Biosystems, USA 
Construction and Transfection of Recombinant Plasmid pcDNA3.1-ING4
The ING4 complementary DNA fragment (GenBank NM_016162) was subcloned into pcDNA3.1(À) by XhoI and EcoRI restriction enzymes to produce pcDNA3.1-ING4 vector. The recombinant plasmid was amplified in Escherichia coli JM109 and was identified by PCR and DNA sequencing. The empty pcDNA3.1(À) was used as a negative control.
The vectors were transfected into human NSCLC cells SPC-A1 with Lipofectamine 2000 reagent using standard transfection procedures. Then, the colonies were selected to produce stable transfectants by adding G418 (600 mg/mL) for 2 weeks. G418-resistant colonies were further verified by RT-PCR and Western blot analysis.
MTT (3-[4,5-dimethylthazol-2-yl]-2,5-diphenyltetrazolium bromide) Assay
The control or transfected SPC-A1 cells were seeded in 96-well plates at a density of 2000 cells/well (200 mL). After culture for 0, 6, 12, 24, 48, and 96 hours, cell viability was measured by the MTT procedure. Twenty microliters of MTT (5 mg/mL) was added to each well, and the plates were then continuously incubated for 4 hours. Reactions were terminated with 200 mL Dimethyl Sulphoxide (DMSO) for 5 minutes. The optical density value was measured at 490 nm wavelength by an ELx800 Automated Microplate Reader (Biotech, USA).
Cell Survival Assay
For the radiosensitivity assay, the cells were X-ray irradiated 24 hours after seeding at different doses of 0, 2, 4, 6, 8, and 10 Gy and at an average dose rate of 100 cGy/min using the X-ray irradiator (ELEKTA Precise Treatment System, Sweden). Immediately following irradiation, the cells were incubated at 37 C with 5% CO 2 . After incubation for 4 days, an MTT assay was performed to evaluate the effect of ING4 overexpression on the cell survival after X-ray irradiation. The surviving fraction at 2 Gy (SF 2Gy ) was calculated. D 37 was defined as the dose that required for 37% surviving fraction.
Colony Formation Assay
Human SPC-A1 cells, transfected with pcDNA3.1(À) or pcDNA-3.1-ING4 plasmid, were seeded onto 6-well plates at 5.0 Â 10 3 cells/well and incubated at 37 C in 5% CO 2 environment. After incubation for 14 days, the colonies were fixed with methanol, stained with crystal violet, and counted manually. Colonyforming efficiency was calculated as colonies/plated cells Â 100%.
Western Blot Analysis
Cells and tissue proteins were extracted in the extraction buffer, and protein concentration was determined by protein assay (Bio-Rad, Canada). The protein lysates were separated on a 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then electroblotted onto polyvinylidene fluoride membrane. Blotting was performed for ING4, Bcl-2, Bax, and caspase-3 with ING4, Bcl-2, Bax, and active caspase-3 primary antibody (Santa Cruz, California), respectively. b-Actin (Sigma, USA) was used as an internal control.
Flow Cytometric Analysis
Cells were harvested and suspended in cold PBS, counting 5 Â 10 5 to 1 Â 10 6 cell/mL. Apoptosis analysis was performed using annexin-V-FITC/PI (fluorescein isothiocyanate/Propidium Iodide) double staining according to the manufacturer's instructions, and apoptotic cells were analyzed using flow cytometry (FACS Calibur; Becton Dickinson, USA).
TdT-Mediated dUTP Nick-End Labeling Assay
Transfected SPC-A1 cells were plated on the slides. Apoptotic cells were detected using the in situ cell death detection kit (Roche, Swiss) according to the manufacturer's instructions. Photos of the slides were taken using an Olympus (Olympus, Japan) fluorescence microscopy. For in vivo assay, the xenograft tissues were cut into 5-mm-thick sections. The tissue sections were assessed by hematoxylin and eosin staining, immunohistochemical staining, and TdT-mediated dUTP nick-end labeling (TUNEL) assay, respectively.
In Vivo Studies
Animal experiments were performed in accordance with the institutional guidelines set forth by the ethics board. The female BALB/c athymic nude mouse (5-6 weeks of age) were purchased from the Experimental Animal Centre of Nanjing Medical University and maintained under pathogen-free conditions (n ¼ 5/group). A total of approximately 5.0 Â 10 6 cells (SPC-A1/pcDNA3.1-ING4 and SPC-A1/pcD NA3.1) were injected subcutaneously (SC) into the posterior flank of nude mouse. Tumor growth was examined weekly for at least 4 weeks. After 28 days, the mice were killed and autopsies performed. Tumor volumes were calculated using the formula:
, where A is the largest diameter and B is the perpendicular diameter. For the radiosensitivity assay, 2 weeks after tumor cell implantation, SPC-A1 SC xenografted tumor-bearing mice were irradiated 10 Gy totally using an X-ray irradiator. Growth delay was calculated 15 days after X-ray irradiation. The primary tumor tissues were used to perform immunostaining analysis of proliferating cell nuclear antigen (PCNA), Bcl-2, and Bax protein.
Statistical Analysis
General statistical and survival analysis was performed by SPSS 10.0 program. Experimental data were expressed as the mean + standard error of the mean (SEM). Statistical significance was determined by Student t test or analysis of variance. All tests performed were 2 sided. P < .05 was considered statistically significant.
Results
ING4 Is Significantly Downregulated in Human NSCLC Tissues
Firstly, the expression of ING4 protein in 28 cases of matched NSCLC and noncancerous lung tissue samples was detected by Western blot assays. As shown in Figure 1A , the average expression level of ING4 protein in NSCLC tissues was significantly lower than that in the corresponding nontumor lung tissues (P < .05). We confirmed these findings by immunostaining analysis of ING4 expression in NSCLC tissues. The ING4 protein was mainly located in the nucleus of normal lung epithelial or tumor cells ( Figure 1B ). Of note, we observed a significant reduction in the expression of ING4 in NSCLC tissues compared with normal tissues, while most tumor cells in the NSCLC samples showed little to no nuclear staining. Interestingly, we found some tumors with ING4 expression in the cytoplasm but lack expression in the nucleus, which needs to be further investigated. These results were consistent with a recent report by Wang et al, 15 suggesting that downregulation of ING4 might play an important role in the initiation and progression of NSCLC. was detected by RT-PCR and Western blot analysis. Reverse transcription PCR and Western blot analysis revealed that the expression of ING4 at messenger RNA and protein level was obviously increased in SPC-A1/pcDNA3.1-ING4 compared with SPC-A1/pcDNA3.1 (Figure 2A and B) . The above results confirmed the expression of the recombinant plasmids in transfected SPC-A1 with pcDNA3.1-ING4, indicating that the exogenous ING4 gene was successfully transfected into SPC-A1 cells.
The Expression of ING4 Was
Overexpression of ING4 Could Suppress In Vitro Growth of NSCLC Cells
To test whether ING4 may function as a tumor suppressor, MTT assay was performed to analyze the effect of ING4 upregulation on the in vitro growth of NSCLC. As shown in Figure  3A , SPC-A1/pcDNA3.1-ING4 cells grew more slowly than SPC-A1/pcDNA3.1 cells. To further testify the antiproliferative effect of ING4 on the growth of NSCLC cells, colony formation assay was performed. Compared with SPC-A1/ pcDNA3.1 cells, the colony numbers of SPC-A1/pcDNA3.1-ING4 cells decreased by about 30% (P < .01; Figure 3B ). Thus, the results of colony formation assay were consistent with those of MTT assay and further indicated that overexpression of ING4 could inhibit in vitro proliferation capacity of NSCLC cells.
Overexpression of ING4 Triggered Apoptosis in NSCLC Cells
To determine whether apoptosis was at the source of the growth inhibition, we further analyzed the apoptosis of SPC-A1 cells with or without exogenous ING4 gene by flow cytometric analysis. Annexin V FITC/PI staining of SPC-A1/ pcDNA3.1-ING4 cells was analyzed by flow cytometry, and a significant increase in the level of apoptotic cells was observed ( Figure 4A ). In the SPC-A1/pcDNA3.1-ING4 cells, the rates of early (lower right quadrant) and late (upper right quadrant) apoptosis were 13.24% + 1.26% and 4.52% + 0.34%, respectively. In contrast, the rates were 3.17% + 0.38% and 2.10% + 0.54%, respectively, in empty vector transfection (P < .01). We confirmed these results by performing a TUNEL assay where we noted a *6-fold increase in levels of apoptotic cells in ING4-transfected SPC-A1 cells (23.13% + 3.62%) compared with pcDNA3.1(À) (3.52% + 1.09%; P < .05; Figure 4B ). Taken together, these results suggest that ectopic expression of ING4 can trigger apoptosis in NSCLC cells.
Effect of ING4 on the In Vitro Sensitivity of NSCLC Cells to Irradiation
The aberrant activation of survival pathways and inactivation of apoptosis pathways in tumor cells can enhance resistance to anticancer treatment. To explore the role of ING4 in cell survival and response to radiotherapy, SPC-A1 cells were transfected with the pcDNA3.1-ING4, and their radiosensitivity to X-ray irradiation was assessed by MTT and flow cytometry assays. We first compared the survival fraction of the cells with escalating doses of irradiation (0-10 Gy). As shown in Figure 5A , there was a significant difference in survival fraction between SPC-A1/pcDNA3.1-ING4 and SPC-A1/pcDNA3.1 cells. SPC-A1/pcDNA3.1-ING4 cells were significantly more sensitive to the cytotoxic effects of X-ray irradiation as shown by a reduction in cell survival rate at 4.0, 6.0, 8.0, and 10.0 Gy (P < .05; Figure 4A ). The D 37 value of SPC-A1/pcDNA3.1-ING4 cells was 5.5 Gy, whereas in control cells, it was 8.7 Gy (Table 1) .
Next, we measured the apoptosis in irradiated SPC-A1 cells by flow cytometry. Compared with irradiation alone, transfection of pcDNA3.1-ING4 enhanced the radiosensitivity of SPC-A1 cells. Twenty-four hours after 6.0 Gy single-dose irradiation, the apoptotic rate of SPC-A1/ pcDNA3.1-ING4 was nearly 3 times higher (28.02% + 1.84%) relative to empty vector control (10.16% + 0.68%; P < .05; Figure 5B ). While at 48 hours, the apoptotic rate was almost identical ( Figure 5C ). In conclusion, our data revealed that upregulation of ING4 could increase the in vitro sensitivity of SPC-A1 cells to X-ray irradiation via the induction of apoptosis. 
Effect of ING4 on the In Vivo Sensitivity of NSCLC Cells to Irradiation
As overexpression of ING4 could increase the radiosensitivity of SPC-A1 cells in vitro, we evaluated the effect of combining ectopic ING4 expression and localized radiation therapy in vivo. SPC-A1 cells transfected with pcDNA3.1-ING4 or pcDNA3.1(À) vector were injected into female nude mice, respectively. Nude mice with established tumor xenografts were treated with localized X-ray irradiation. Interestingly, we found that tumors derived from SPC-A1 cells/pcDNA3.1-ING4 grew substantially slowly, compared to the control mice Figure 6A ). The apoptotic rate of tumors measured by TUNEL assay in SPC-A1/pcDNA3.1-ING4 (20.83% + 2.24%) cells was approximately 6-fold than that of tumors in control cells (3.50% + 1.51%; P < .01; Figure 6B ).
To investigate whether the upregulation of ING4 could potentiate the inhibition of tumor growth by irradiation in vivo, tumor-bearing mice were irradiated with 10 Gy of X-ray. The results of the tumor growth curve showed that tumor growth was retarded by radiation alone ( Figure 6A ). Moreover, the therapeutic effect of ING4 overexpression was more significant than that of radiation alone. Furthermore, the radiation effect on tumor xenografts was enhanced by combined ING4 overexpression. Exposure to 10 Gy irradiation treatment resulted in a decrease in the volume of the xenografts to 615 + 43 vs 942 + 18 mm 3 (P < .05, Figure 6A ). These results suggest that ING4 was significantly associated with in vivo proliferation and apoptosis capacity of NSCLC cells, and restoration of ING4 function reversed the radioresistance of NSCLC cells to X-ray irradiation.
Effects of ING4 on the Survival Pathways of NSCLC Cells
To further explore the mechanisms underlying the ING4-induced growth suppression and proapoptotic function in SPC-A1 cells, we analyzed the expression of apoptosisrelated proteins by immunoblotting. Activation of caspase-3 was found in SPC-A1/pcDNA3.1-ING4 cells compared with SPC-A1/pcDNA3.1(À) cells, suggesting that the ectopic expression of ING4 might induce apoptosis in NSCLC cells in a caspase-3-dependent manner ( Figure 7A ). We also measured the expression of the antiapoptotic protein, Bcl-2, and found that levels of Bcl-2 decreased with overexpression of ING4 ( Figure 7A ). Immunostaining analysis revealed that the positive rate of PCNA in SPC-A1/ pcDNA3.1-ING4-positive tumors significantly decreased relative to controls ( Figure 7B ), suggesting that ING4 downregulates proliferation in vivo. We also assessed the levels of Bcl-2 and Bax in nude mice xenografts by immunohistochemistry. We detected Bcl-2 and Bax at the plasma membrane and in the plasma ( Figure 7B ). Higher expression of Bax and lower expression of Bcl-2 were observed in xenografts of SPC-A1/pcDNA3.1-ING4 compared with those of SPC-A1/pcDNA3.1(À).
Discussion
Inhibitor of growth family members play important roles in tumorigenesis, cell apoptosis, and angiogenesis. Inhibitor of growth 4 was first identified in 2003 by searching for homology with ING1, the founding member of ING family proteins. 6 Inhibitor of growth 4 was found to be significantly downregulated in lung carcinoma, 12 breast cancer, 14 head and neck squamous cell carcinomas, 11 colorectal cancer, 13 and astrocytoma, 19 corroborating our findings in NSCLC. In this study, we showed that ING4 expression was markedly decreased in NSCLC tissues compared with corresponding nontumor lung tissues. Moreover, most tumor cells in the NSCLC samples showed little to no nuclear staining, indicating that ING4 gene was associated with initiation and progression of lung cancer. Taken together, ING4 gene could be served as a diagnostic marker for human malignancies. As the size of tissue samples in this study was limited, further investigation in a larger patient cohort is necessary to confirm its clinical significance in NSCLC. Evidence also shows that the ING4 gene is frequently mutated in various cancer cell lines. 17 The N214D mutation dramatically dampened the ability of ING4 to inhibit proliferation, anchorage-independent growth, or cell migration or to sensitize to cell death. The N214D mutation also correlates with reduced protein stability of ING4 due to increased proteasome-mediated degradation. 17 Recently, Li and his colleagues reported that ING4 was induced by breast cancer melanoma suppressor 1-inhibited melanoma angiogenesis. 23 However, the molecular mechanism for ING4 downregulation in human cancers is currently unclear and needs to be further elucidated.
Inhibitor of growth 4 is known to bind p53 via its NLS region and enhance the transcriptional activity of p53. 6, 32 Recent studies found that transient ING4 expression, which is dependent on Myc and Phosphatase and Tensin Homolog (PTEN), is absolutely required for the prostate epithelial differentiation. And ING4 is lost in the majority of human prostate cancers. 33 As a candidate tumor suppressor gene, ING4 may affect tumor inhibition via multiple pathways. Overexpression of ING4 enhanced the chemosensitivity of cells to the anticancer agents, CDDP, doxorubicin, and etoposide in hepatocellular carcinoma cells. 20, 21 Meanwhile, Xie et al showed that adenovirus-mediated ING4 plus cisplatin (CDDP) has an in vitro-and in vivo-enhanced antitumor effect associated with the cooperative regulation of extrinsic and intrinsic apoptotic pathways in hepatocarcinoma cells SMMC-7721. 21 Our previous studies have found a decreasing level of ING4 expression occurred in docetaxel-resistant lung adenocarcinoma tissues. And overexpression of ING4 enhanced the sensitivity of SPC-A1 cells to docetaxel. 31, 34 In the present study, we found that overexpression of ING4 could significantly affect the growth of NSCLC cells both in vitro and in vivo, and the SPC-A1 cell growth inhibition by ectopic ING4 expression might be associated with caspase-3-dependent apoptosis enhancement. In addition, our findings showed that overexpression of ING4 in NSCLC cells led to a reversal of the Bcl-2/Bax ratio, which finally induced activation of caspase-3. Functional genomics screening utilizing mutant mouse embryonic stem cells identified that ING4 was implicated in radiation response. 35 Zhao et al found that the combination of ING4 gene and 25 I radiation therapy had a synergistic effect in pancreatic cancer cell growth suppression and apoptosis induction. 36 Until recently, very few studies have been performed to explore the molecular mechanisms of ING4 in modulating the radiosensitivity to X-ray irradiation in NSCLC. In this study, our functional results confirmed that exogenous ING4 significantly increased the radiosensitivity of SPC-A1 cells to X-ray irradiation in vitro and in vivo. Therefore, these data suggest that appropriate combination of X-ray application with ING4 might be a potential approach to NSCLC therapy. For higher dose, X-ray would produce potentially serious toxic effects such as radiation esophagitis and lung fibrosis, and combination of X-ray with ING4 upregulation for the treatment of NSCLC would contribute to lower dose X-ray exposure and result in a reduction of X-ray toxic side effects. However, whether the upregulation of ING4 in human SPC-A1 cells enhanced radiosensitivity through mitochondrial apoptosis pathway needs to be further elucidated. Many experiments investigated that ING4 also plays a critical role in tumor invasion and migration. Garkavtsev et al firstly reported that ING4 could inhibit brain tumor growth and angiogenesis by associating with p65 (RelA) subunit of NFkB. 10 Inhibitor of growth 4 and NF-kB interact, but the interaction doesn't prevent NF-kB activation or DNA-binding activity. Inhibitor of growth 4 could attenuate NF-kB-mediated activities to reduce the expression of NF-kB-regulated genes, Cox-2 and MMP-9.
10, 23 Li and his colleagues reported inhibited melanoma angiogenesis by suppressing NF-kB activity and IL-6 expression. 23 Therefore, we propose that the absence of proper ING4 activities may enable already activated NF-kB to perpetually induce the expression of genes that contribute to tumorigenesis.
Conclusion
In summary, the current study revealed that frequent downregulation of ING4 is observed in NSCLC and shown that ING4 functions as a tumor suppressor gene in NSCLC. Our experimental data may provide a new insight that combination of ING4 upregulation and X-ray irradiation might be a potential strategy for the treatment of human NSCLC in future. 
